1401P - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours

Abstract

BackgroundPeptide receptor radionuclide therapy (PRRT) is an established treatment modality for advanced midgut neuroendocrine tumours (NET) (1), based on the presence of somatostatin receptors (SSTR). This therapy should be effective for SSTR expressing NETs from all sites of origin. SSTR expression correlates with grade, with higher expression seen in lower grade disease (2). No trials of PRRT have been undertaken in patients with typical carcinoid (TC) or atypical carcinoid (AC) of bronchial origin. Most guidelines for bronchopulmonary NET either do not comment on PRRT or acknowledge lack of data. However, small retrospective case series, reporting 11 to 34 patients, suggest potential benefit from lutetium (177Lu)-based PRRT (3-10). MethodsWe undertook a retrospective chart review of patients with TC and AC who had received at least one dose of lutetium-based PRRT in six major NET centres across Australia. Demographics, histopathology and information on clinical course were collected. ResultsData was collected from 53 patients treated across six centres between January 2002 and 2019. Patient details from four centres are presented in the table. Each of these four centres had 1, 8, 9 and 15 eligible patients respectively. Of these 33 patients, 22 are still alive, with the duration of follow up post the first cycle of PRRT ranging from 3 to 67 months. Analysis of the whole cohort for treatment, dose, response, patient and disease outcomes will be presented.Table1401P Clinical characteristics (Four centres in South Australia, Victoria, New South Wales)TableGenderNumber (n=33)Male22 (67%)Female11 (33%)Age (years)<7021 (64%)≥7012 (36%)HistopathologyTC12 (36%)AC21 (64%)Current statusAlive22 (67%)Dead11 (33%) ConclusionsThis is the largest series of patients with bronchial carcinoid treated with PRRT to be reported to date. Evaluation of lutetium-based PRRT in a prospective clinical trial is of interest to validate its efficacy as a therapeutic option. Legal entity responsible for the studyMonash Health. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.